Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The Korea Exchange set and announced the ex-dividend reference price for Celltrion’s common shares at KRW 182,900, effective December 27, 2024, to reflect its stock dividend. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Ex-Dividend Reference Price Implementation…

Read More “[Disclosure] Celltrion (068270) – Notice of Ex-Dividend Reference Price / 2024-12-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary At Alteogen’s Extraordinary General Meeting of Shareholders, a single agenda item regarding amendments to the Articles of Incorporation (Agenda 1) was approved as originally submitted. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Approved Articles of Incorporation Amendments…

Read More “[Disclosure] ALTEOGEN (196170) – Results of Extraordinary General Shareholders Meeting / 2024-12-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following Celltrion’s stock dividend resolution (announced on Dec 13, 2024), the Korea Exchange (KRX) implemented market measures including adjustments to base prices, contract multipliers (10.47225038), and strike prices for Celltrion equity futures and options, effective December 27, 2024. 📊 Key Disclosure Content & Financial Highlights 📝…

Read More “[Disclosure] Celltrion (068270) – Notice of Equity Futures & Options Market Measures (Adjustment Due to Stock Dividend) / 2024-12-26” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen received an advance notice of unfaithful disclosure corporation designation from the Korea Exchange due to two disclosure reversals (cancellation of subsidiary merger and stock acquisition), with the final determination deadline set for January 20, 2025. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment…

Read More “[Disclosure] ALTEOGEN (196170) – Advance Notice of Unfaithful Disclosure Corporation Designation (2 Cases of Disclosure Reversal) / 2024-12-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received marketing authorization from the Ministry of Food and Drug Safety (MFDS) of South Korea for Avtozma (CT-P47), a biosimilar referencing Actemra, covering major indications including adult rheumatoid arthritis. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of…

Read More “[Disclosure] Celltrion (068270) – Approval of Korean MFDS Marketing Authorization for Avtozma (CT-P47, Actemra Biosimilar) / 2024-12-23” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Regarding media reports on a KRW 200B Redeemable Convertible Preferred Stock (RCPS) issuance, Alteogen clarified in this follow-up disclosure that while discussions are ongoing, nothing has been decided and no lead manager contract has been executed. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment…

Read More “[Disclosure] ALTEOGEN (196170) – Clarification on Rumors or News Reports (Unconfirmed) / 2024-12-20” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company, extending the disclosure postponement deadline for the counterparty’s identity from December 31, 2024, to December 31, 2030, upon the customer’s request. 📊…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-12-19” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company, extending the disclosure postponement deadline for the counterparty’s identity from December 31, 2024, to December 31, 2030, upon the customer’s request. 📊…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-12-19” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its pharmaceutical contract manufacturing agreement with a US-based pharmaceutical company, extending the contract end date and disclosure postponement deadline from December 31, 2024, to December 31, 2026, upon the customer’s request. 📊 [Key Disclosure Details & Financial Figures]…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2024-12-18” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its new facility investment in Plant 5 at Songdo 2nd Bio Campus, updating the total investment amount from KRW 1.9801T to KRW 2.0098T. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) New Facility Investment / 2024-12-18” »